Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Niraparib With Dostarlimab Therapy as Neoadjuvant Treatment for Patients With BRCA-mutated Breast Cancer
NCT04584255Phase 2Active, not recruiting
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Jan 2021
- Primary completion
- Jul 2025
- Modality
- Immune Checkpoint Inhibitors, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of niraparib, dostarlimab in breast cancer, sponsored by Dana-Farber Cancer Institute. Started Jan 2021; status: active, not recruiting.
02
Drugs
niraparibdostarlimab
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT04584255.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04584255.